[1]
Cilurzo, F.; Gennari, C.G.M.; Selmin, F.; Franzé, S.; Musazzi, U.M.; Minghetti, P. On the characterization of medicated plasters containing NSAIDs according to novel indications of USP and EMA: Adhesive property and in vitro skin permeation studies. Drug Dev. Ind. Pharm., 2015, 41(2), 183-189.
[2]
Cilurzo, F.; Casiraghi, A.; Selmin, F.; Minghetti, P. Supersaturation as a tool for skin penetration enhancement. Curr. Pharm. Design., 2015, 20, 2733-2744.
[3]
Hadgraft, J.; Lane, M.E. Drug crystallization - implications for topical and transdermal delivery. Exp Opin. Drug Deliv., 2016, 13(6), 817-830.
[4]
Cilurzo, F.; Alberti, E.; Minghetti, P.; Gennari, C.G.M.; Casiraghi, A.; Montanari, L. Effect of drug chirality on the skin permeability of ibuprofen. Int. J. Pharm., 2010, 386(1-2), 71-76.
[5]
Angamuthu, M.; Shankar, V.K.; Murthy, S.N. Water activity and its significance in topical dosage forms. J. Pharm. Sci., 2018, 107(6), 1656-1666.
[6]
Belsey, N.A.; Garrett, N.L.; Contreras-Rojas, L.R.; Pickup-Gerlaugh, A.J.; Price, G.J.; Moger, J.; Guy, R.H. Evaluation of drug delivery to intact and porated skin by coherent Raman scattering and fluorescence microscopies. J. Control. Release, 2014, 174(1), 37-42.
[7]
Huang, X.; Tanojo, H.; Lenn, J.; Deng, C.H.; Krochmal, L. A novel foam vehicle for delivery of topical corticosteroids. J. Am. Acad. Dermat., 2005, 53(1), S26-S38.
[8]
Tamarkin, D.; Friedman, D.; Shemer, A. Emollient foam in topical drug delivery. Expert Opin. Drug Deliv., 2006, 3, 799-807.
[9]
Zhao, Y.; Moddaresi, M.; Jones, S.A.; Brown, M.B. A dynamic topical hydrofluoroalkane foam to induce nanoparticle modification and drug release in situ. Eur. J. Pharm. Biopharm., 2009, 72, 521-528.
[10]
Zhao, Y.; Brown, M.B.; Jones, S.A. The topical delivery of benzoyl peroxide using elegant dynamic hydrofluoroalkane foams. J. Pharm. Sci., 2010, 99(3), 1384-1398.
[11]
Zhao, Y.; Brown, M.B.; Jones, S.A. The effects of particle properties on nanoparticle drug retention and release in dynamic minoxidil foams. Int. J. Pharm., 2010, 383, 277-284.
[12]
Lind, M. Supersaturation of Calcipotriene and Betamethasone Dipropionate in a novel aerosol foam formulation for topical treatment of psoriasis provides enhanced bioavailability of the active ingredients. Dermatol. Ther. (Heidelb.), 2016, 6(3), 413-425.
[13]
Aguzzi, C.; Rossi, S.; Bagnasco, M.; Lanata, L.; Sandri, G.; Bona, F.; Ferrari, F.; Bonferoni, M.C.; Caramella, C. Penetration and distribution of thiocolchicoside through human skin: Comparison between a commercial foam (Miotens®) and a drug solution. AAPS PharmSciTech, 2008, 9(4), 1185-1190.
[14]
Mirtič, J.; Papathanasiou, F.; Temova Rakuša, Ž. GosencaMatjaž, M.; Roškar, R.; Kristl, J. Development of medicated foams that combine incompatible hydrophilic and lipophilic drugs for psoriasis treatment. Int. J. Pharm., 2017, 524(1-2), 65-76.
[15]
Blume-Peytavi, U.; Massoudy, L.; Patzelt, A.; Lademann, J.; Dietz, E.; Rasulev, U.; Bartels, N.G. Follicular and percutaneous penetration pathways of topically applied minoxidil foam. Eur. J. Pharm. Biopharm., 2010, 76, 450-453.
[16]
Jarratt, M.; Werner, C.P.; Alió Saenz, A.B. Tazarotene Foam versus tazarotene gel: A randomized relative bioavailability study in acne vulgaris. Clin. Drug Investig., 2013, 33, 283.
[17]
Draelos, Z.D.; Elewski, B.E.; Harper, J.C.; Sand, M.; Staedtler, G.; Nkulikiyinka, R.; Shakery, K. A phase 3 randomized, double-blind, vehicle-controlled trial of azelaic acid foam 15% in the treatment of papulopustular rosacea. Cutis, 2015, 96, 54-61.
[18]
Bensignor, E.J.; Fabriès, L.J. Use of antipruritic and rehydrating foams on localized lesions of atopic dermatitis in dogs: A small-scale pilot and comparative double-blinded study. Vet. Dermatol., 2018, 29(5), 446-e150.
[19]
Elewski, B.E.; Vlahovic, T.C. Econazole nitrate foam 1% for the treatment of tinea pedis: Tesults from two double-blind, vehicle-controlled, phase 3 clinical trials. J. Drugs Dermatol., 2014, 13(7), 803-808.
[20]
Feldman, S.R.; Werner, C.P.; Saenz, A.B.A. The efficacy and tolerability of tazarotene foam, 0.1%, in the treatment of acne vulgaris in 2 multicenter, randomized, vehicle-controlled, double-blind studies. J. Drugs Dermatol., 2013, 12(4), 438-446.
[21]
Zhao, Y.; Brown, M.B.; Jones, S.A. Pharmaceutical foams: Are they the answer to the dilemma of topical nanoparticles? Nanomedicine, 2010, 6, 227-236.
[22]
Bikerman, J.J. Foams, 1st ed; Springer-Verlag Berlin Heidelberg: New York, 1973.
[23]
Arzhavitina, A.; Steckel, H. Foams for pharmaceutical and cosmetic application. Int. J. Pharm., 2010, 394(1-2), 1-17.
[24]
Vervaet, C.; Byron, P.R. Drug-surfactant-propellant interactions in HFA-formulations. Int. J. Pharm., 1999, 186(1), 13-30.
[25]
McDonald, K.J.; Martin, G.P. Transition to CFC-free metered dose inhalers - into the new millennium. Int. J. Pharm., 2000, 201, 89-107.
[26]
Murray, B.S.; Ettelaie, R. Foam stability: proteins and nanoparticles. Curr. Opin. Colloid Interface Sci., 2004, 9, 314-320.
[27]
Roberts, K.; Axberg, C.; Österlund, R. In: Foams; Akers, R.J., Ed.; Academic Press: London, 1976; pp. 39-51.
[28]
Müller, R.H. In: Pharmazeutische Technologie: Moderne Arzneiformen; , 1997; 26, p. 323.
[29]
Kroepke, R.; Bleckmann, A.; Riedel, H.; Rohde, O.; Trau, J. Cosmetic post-foaming preparations with secondary propellant to achieve cooling effect.Patent EP 1391192 A1, 25 February 2004.
[30]
Kealy, T.; Abramb, A.; Hunt, B.; Buchta, R. The rheological properties of pharmaceutical foam: Implications for use. Int. J. Pharm., 2008, 355, 67-80.
[31]
Buchta, R.; Ding, S.; Hickey, A.; Houghton, M.; Noland, P.; Tice, T.; Warner, K.; Brown, W. Pharmaceutical Foams. Pharmacopeial forum, 2017, 43(1), 1-21.
[32]
Gennari, C.; Selmin, F.; Franzè, S.; Musazzi, U.M.; Quaroni, G.M.G.; Casiraghi, A.; Cilurzo, F. A glimpse in critical attributes to design cutaneous film forming systems based on ammonium methacrylate. J. Drug Deliv. Sci. Technol., 2017, 41, 157-163.
[33]
Lecomte, F.; Siepmann, J.; Walther, M.; MacRae, R.J.; Bodmeier, R. Polymer blends used for the coating of multiparticulates: comparison of aqueous and organic coating techniques. Pharm. Res., 2004, 21(5), 882-890.
[34]
Siepmann, F.; Siepmann, J.; Walther, M.; MacRae, R.J.; Bodmeier, R. Polymer blends for controlled release coatings. J. Control. Release, 2008, 125(1), 1-15.
[35]
Felton, L.A. Mechanisms of polymeric film formation. Int. J. Pharm., 2013, 457(2), 423-427.
[36]
Bauer, K.H.; Lehmann, K.; Osterwald, H.P.; Rothgang, G. Coated Pharmaceutical Dosage Forms; CRC Press: Boca Raton, FL, 1998.
[37]
Cilurzo, F.; Selmin, F.; Vistoli, G.; Minghetti, P.; Montanari, L. Binary polymeric blends to microencapsulate nitroflurbiprofen: Physicochemical and in silico studies. Eur. J. Pharm. Sci., 2007, 31(3-4), 202-210.
[38]
Frederiksen, K.; Guy, R.H.; Petersson, K. The potential of polymeric film-forming systems as sustained delivery platforms for topical drugs. Expert Opin. Drug Deliv., 2016, 13(3), 349-360.
[39]
Zurdo Schroeder, I.; Franke, P.; Schaefer, U.F.; Lehr, C-M. Development and characterization of film forming polymeric solutions for skin drug delivery. Eur. J. Pharm. Biopharm., 2007, 65(1), 111-121.
[40]
Algin, Y.E. Inal. Ö. Transdermal spray in hormone delivery. Trop. J. Pharm. Res., 2014, 13(3), 469-474.
[41]
Lu, W.; Luo, H.; Wu, Y. Preparation and characterization of a metered dose transdermal spray for testosterone. Acta Pharm. Sin. B, 2013, 3(6), 392-399.
[42]
Cilurzo, F.; Selmin, F.; Gennari, C.G.M.; Montanari, L.; Minghetti, P. Application of methyl methacrylate copolymers to the development of transdermal or loco-regional drug delivery systems. Expert Opin. Drug Deliv., 2014, 11(7), 1033-1045.
[43]
Mundada, A.S.; Avari, J.G. Novel biomaterial for transdermal application: In vitro and in vivo characterization. Drug Deliv., 2011, 18(6), 424-431.
[44]
Gennari, C.G.M.; Selmin, F.; Ortenzi, M.A.; Franzè, S.; Musazzi, U.M.; Casiraghi, A.; Minghetti, P.; Cilurzo, F. In situ film forming fibroin gel intended for cutaneous administration. Int. J. Pharm., 2006, 511, 296-302.
[45]
Bigucci, F.; Abruzzo, A.; Saladini, B.; Gallucci, M.C.; Cerchiara, T.; Luppi, B. Development and characterization of chitosan/hyaluronan film for transdermal delivery of thiocolchicoside. Carbohydr. Polym., 2015, 130, 32-40.
[46]
Patel, V.F.; Liu, F.; Brown, M.B. Advances in oral transmucosal drug delivery. J. Control. Release, 2011, 153, 106-116.
[47]
Cilurzo, F.; Gennari, C.G.M.; Minghetti, P. Adhesive properties: A critical issue in transdermal patch development. Exp Op. Drug Deliv., 2012, 9(1), 33-45.
[50]
Williams, A.C.; Barry, B.W. Penetration enhancers. Adv. Drug Del. Rev., 2004, 56(5), 603-618.
[51]
Pham, Q.D.; Topgaard, D.; Sparr, E. Tracking solvents in the skin through atomically resolved measurements of molecular mobility in intact stratum corneum. Proc. Natl. Acad. Sci. USA, 2017, 114(2), E112-E121.
[52]
Garvie-Cook, H.; Frederiksen, K.; Petersson, K.; Guy, R.H.; Gordeev, S. Characterization of topical film-forming systems using atomic force microscopy and Raman microspectroscopy. Mol. Pharm., 2015, 12(3), 751-757.
[53]
Herrmann, S.; Daniels, R.; Lunter, D. Methods for the determination of the substantivity of topical formulations. Pharm. Develop. Technol., 2017, 22(4), 487-491.
[54]
Frederiksen, K.; Guy, R.H.; Petersson, K. Formulation considerations in the design of topical, polymeric film-forming systems for sustained drug delivery to the skin. Eur. J. Pharm. Biopharm., 2015, 91, 9-15.
[55]
Garvie-Cook, H.; Frederiksen, K.; Petersson, K.; Guy, R.H.; Gordeeva, S.N. Biophysical elucidation of the mechanism of enhanced drug release and topical delivery from polymeric film-forming systems. J. Control. Release, 2015, 212, 103-112.
[56]
Schroeder, I.Z.; Franke, P.; Schaefer, U.F. Delivery of ethinylestradiol from film forming polymeric solutions across human epidermis in vitro and in vivo in pigs. J. Control. Release, 2007, 118(2), 196-203.
[57]
Ammar, H.O.; Ghorab, M.; Mahmoud, A.A.; Makram, T.S.; Ghoneim, A.M. Rapid pain relief using film forming polymeric solution of ketorolac. Pharm. Dev. Tech., 2013, 18(5), 1005-1016.
[58]
Sritharadol, R.; Nakpheng, T.; Heng, P.W.S.; Srichana, T. Development of a topical mupirocin spray for antibacterial and wound-healing applications. Drug Dev. Ind. Pharm., 2017, 43(10), 1715-1728.
[59]
Bakshi, A.; Bajaj, A.; Malhotra, G. A novel metered dose transdermal spray formulation for oxybutynin. Indian J. Pharm. Sci., 2008, 70(6), 733-739.
[60]
Edwards, A.; Qi, S.; Liu, F.; Brown, M.B.; McAuley, W.J. Rationalising polymer selection for supersaturated film forming systems produced by an aerosol spray for the transdermal delivery of methylphenidate. Eur. J. Pharm. Biopharm., 2017, 114, 164-174.
[61]
Ranade, S.; Bajaj, A.; Londhe, V.; Babul, N.; Kao, D. Fabrication of topical metered dose film forming sprays for pain management. Eur. J. Pharm. Sci., 2017, 100, 132-141.
[62]
Reid, M.L.; Benaouda, F.; Khengar, R. Topical corticosteroid delivery into human skin using hydrofluoroalkane metered dose aerosol sprays. Int. J. Pharm., 2013, 452(1-2), 157-165.
[63]
Lu, W.; Luo, H.; Zhu, Z.; Wu, Y.; Luo, J.; Wang, H. Preparation and the biopharmaceutical evaluation for the metered dose transdermal spray of dexketoprofen. J. Drug Deliv., 2014, 2014, 1-12.
[64]
Gohel, M.C.; Nagori, S.A. Fabrication of modified transport fluconazole transdermal spray containing ethyl cellulose and Eudragit® RS100 as film formers. AAPS PharmSciTech, 2009, 10(2), 684-691.
[65]
Malik, R.; Venkatesh, K.S.; Dwivedi, A.K.; Misra, A. Episodic transdermal delivery of testosterone. Mol. Pharm., 2012, 9, 1537-1543.
[66]
Heck, R.; Hermann, S.; Lunter, D.J.; Daniels, R. Film-forming formulations containing porous silica for the sustained delivery of actives to the skin. Eur. J. Pharm. Biopharm., 2016, 108, 1-8.
[67]
Heck, R.; Lukić, M.Ž.; Savić, S.D.; Daniels, R.; Lunter, D.J. Ex vivo skin permeation and penetration of nonivamide from and in vivo skin tolerability of film-forming formulations containing porous silica. Eur. J. Pharm. Sci., 2017, 106, 34-40.
[68]
Lunter, D.J.; Daniels, R. New film forming emulsions containing Eudragit® NE and/or RS 30D for sustained dermal delivery of nonivamide. Eur. J. Pharm. Biopharm., 2012, 82(2), 291-298.
[69]
Guo, R.; Du, X.; Zhang, R.; Deng, L.; Dong, A.; Zhang, J. Bioadhesive film formed from a novel organic-inorganic hybrid gel for transdermal drug delivery system. Eur. J. Pharm. Biopharm., 2011, 79, 574-583.
[70]
Oh, D-W.; Kang, J-H.; Lee, H-J.; Han, S-D.; Kang, M-H.; Kwon, Y-H.; Jun, J-H.; Kim, D-W.; Rhee, Y-S.; Kim, J-Y.; Park, E-S.; Park, C-W. Formulation and in vitro/in vivo evaluation of chitosan-based film forming gel containing ketoprofen. Drug Deliv., 2017, 24(1), 1056-1066.
[71]
Li, X.; Zhang, R.; Liang, R.; Liu, W.; Wang, C.; Su, Z.; Sun, F.; Li, Y. Preparation and characterization of sustained-release rotigotine film-forming gel. Int. J. Pharm., 2014, 460, 273-279.
[72]
Liu, X.; Fu, L.; Dai, W.; Liu, W.; Zhao, J.; Wu, Y.; Teng, L.; Sun, F.; Li, Y. Design of transparent film-forming hydrogels of tolterodine and their effects on stratum corneum. Int. J. Pharm., 2014, 471, 322-331.
[73]
Rao, P.R.; Diwan, P.V. Permeability studies of cellulose acetate free films for transdermal use: influence of plasticizers. Pharm. Acta Helv., 1997, 72, 47-51.
[74]
Otto, A.; du Plessis, J.; Wiechers, J.W. Formulation effects of topical emulsions on transdermal and dermal delivery. Int. J. Cosmet. Sci., 2009, 31(1), 1-19.
[75]
Bonina, F.P.; Puglia, C.; Trombetta, D.; Dragani, M.C.; Gentile, M.M.; Clavenna, G. Vehicle effects on in vitro skin permeation of thiocolchicoside. Pharmazie, 2002, 57(11), 750-752.
[76]
Mitra, A.; Wu, Y. Topical delivery for the treatment of psoriasis. Expert Opin. Drug Deliv., 2010, 7(8), 977-992.
[77]
Su, Y-H.; Fang, J-Y. Drug delivery and formulations for the topical treatment of psoriasis. Expert Opin. Drug Deliv., 2008, 5(2), 235-249.
[78]
Kaur, I.P.; Kakkar, S. Topical delivery of antifungal agents. Expert Opin. Drug Deliv., 2010, 7(11), 1303-1327.
[79]
Franz, T.J.; Parsell, D.A.; Halualani, R.M.; Hannigan, J.F. Kalbach. JP.; Harkonen, W.S. Betamethasone valerate foam 0.12%: A novel vehicle with enhanced delivery and efficacy. Int. J. Dermatol., 1999, 38, 628-632.
[80]
Santos, P.; Watkinson, A.C.; Hadgraft, J.; Lane, M.E. Influence of penetration enhancer on drug permeation from volatile formulations. Int. J. Pharm., 2012, 439(1-2), 260-268.
[81]
Ibrahim, S.A. Spray-on transdermal drug delivery systems. Expert Opin. Drug Deliv., 2015, 12(2), 195-205.
[82]
Cilurzo, F.; Musazzi, U.M.; Franzé, S.; Fedele, G.; Minghetti, P. Design of in vitro skin permeation studies according to the EMA guideline on quality of transdermal patches. Eur. J. Pharm. Sci., 2018, 125, 86-92.
[83]
Sitruk-Ware, R.; Nath, A.; Mishell, D.R., Jr Contraception technology: past, present and future. Contraception, 2013, 87(3), 319-330.
[84]
Vrijens, B.; De Geest, S.; Hughes, D.A. A new taxonomy for describing and defining adherence to medications. Br. J. Clin. Pharmacol., 2012, 73(5), 691-705.
[85]
Tan, X.; Feldman, S.R.; Chang, J.; Balkrishnan, R. Topical drug delivery systems in dermatology: A review of patient adherence issues. Expert Opin. Drug Deliv., 2012, 9(10), 1263-1271.
[86]
Devaux, S.; Castela, A.; Archier, E.; Gallini, A.; Joly, P.; Misery, L.; Aractingi, S.; Aubin, F.; Bachelez, H.; Cribier, B.; Jullien, D.; Le Maître, M.; Richard, M.A.; Ortonne, J.P.; Paul, C. Adherence to topical treatment in psoriasis: A systematic literature review. J. Eur. Acad. Dermatol. Venereol., 2012, 26(3), 61-67.
[87]
Felix, K.; Unrue, E.; Inyang, M.; Cardwell, L.A.; Oussedik, E.; Richardson, I.; Feldman, S.R. Patients’ preferences for different corticosteroid vehicles are highly variable. J. Dermatolog. Treat., 2018, 17, 1-18.
[88]
Kienzler, J.L.; Queille-Roussel, C.; Mugglestone, C.J. Stratum corneum pharmacokinetics of the anti-fungal drug, terbinafine, in a novel topical formulation, for single- dose application in dermatophytoses. Curr. Med. Res. Opin., 2007, 23(6), 1293-1302.
[89]
Brown, M.; Evans, C.; Muddle, A. Efficacy, tolerability and consumer acceptability of terbinafine topical spray versus terbinafine topical solution: A phase IIa, randomised, observer-blind, comparative study. Am. J. Clin. Dermatol., 2013, 14(5), 413-419.
[90]
Williams, A.C. Transdermal and topical drug delivery - from theory to clinical practice. Pharmaceutical Press: London, 2003, 4, pp. (1)49-50.
[91]
Hong, C.H.; Papp, K.A.; Lophaven, K.W.; Skallerup, P.; Philipp, S. Patients with psoriasis have different preferences for topical therapy, highlighting the importance of individualized treatment approaches: randomized phase IIIb PSO-INSIGHTFUL study. J. Eur. Acad. Dermatol. Venereol., 2017, 31(11), 1876-1883.
[92]
Gorelick, J.; Cantrell, W.; Kucera, K.; Veverka, K.A.; Gooding, K. Patient-reported satisfaction with the fixed combination calcipotriene/betamethasone dipropionate foam for plaque psoriasis. J. Drugs Dermatol., 2018, 17(8), 880-884.
